1. Biochemistry and Chemical Biology
  2. Cell Biology

Elongation inhibitors do not prevent the release of puromycylated nascent polypeptide chains from ribosomes

  1. Benjamin D Hobson
  2. Linghao Kong
  3. Erik W Hartwick
  4. Ruben L Gonzalez
  5. Peter A Sims  Is a corresponding author
  1. Columbia University Irving Medical Center, United States
  2. Columbia University, United States
https://doi.org/10.7554/eLife.60048
Share this article
Cite this article
  1. Benjamin D Hobson
  2. Linghao Kong
  3. Erik W Hartwick
  4. Ruben L Gonzalez
  5. Peter A Sims
(2020)
Elongation inhibitors do not prevent the release of puromycylated nascent polypeptide chains from ribosomes
eLife 9:e60048.
https://doi.org/10.7554/eLife.60048
  2. Download BibTeX
  3. Download .RIS

Abstract

Puromycin is an amino-acyl transfer RNA analog widely employed in studies of protein synthesis. Since puromycin is covalently incorporated into nascent polypeptide chains, anti-puromycin immunofluorescence enables visualization of nascent protein synthesis. A common assumption in studies of local messenger RNA translation is that the anti-puromycin staining of puromycylated nascent polypeptides in fixed cells accurately reports on their original site of translation, particularly when ribosomes are stalled with elongation inhibitors prior to puromycin treatment. However, when we attempted to implement a proximity ligation assay to detect ribosome-puromycin complexes, we found no evidence to support this assumption. We further demonstrated, using biochemical assays and live cell imaging of nascent polypeptides in mammalian cells, that puromycylated nascent polypeptides rapidly dissociate from ribosomes even in the presence of elongation inhibitors. Our results suggest that attempts to define precise subcellular translation sites using anti-puromycin immunostaining may be confounded by release of puromycylated nascent polypeptide chains prior to fixation.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for all Figures.

The following previously published data sets were used

Article and author information

Author details

  1. Benjamin D Hobson

    Depart of Systems Biology, Medical Scientist Training Program, Columbia University Irving Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2745-5318

  2. Linghao Kong

    Depart of Systems Biology, Columbia University Irving Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Erik W Hartwick

    Department of Chemistry, Columbia University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Ruben L Gonzalez

    Department of Chemistry, Columbia University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1344-5581

  5. Peter A Sims

    Depart of Systems Biology, Department of Biochemistry & Molecular Biophysics, Columbia University Irving Medical Center, New York, United States
    For correspondence
    pas2182@cumc.columbia.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3921-4837

Funding

National Institutes of Health (R33CA202827)

  • Peter A Sims

National Institutes of Health (F30 DA047775)

  • Benjamin D Hobson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Hobson et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,781
    views
  • 557
    downloads
  • 34
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Benjamin D Hobson
  2. Linghao Kong
  3. Erik W Hartwick
  4. Ruben L Gonzalez
  5. Peter A Sims
(2020)
Elongation inhibitors do not prevent the release of puromycylated nascent polypeptide chains from ribosomes
eLife 9:e60048.
https://doi.org/10.7554/eLife.60048

Share this article

https://doi.org/10.7554/eLife.60048

Categories and tags

Research organisms

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology

    Puromycin reactivity does not accurately localize translation at the subcellular level

    Syed Usman Enam, Boris Zinshteyn ... Rachel Green
    Research Article Updated

    Puromycin is a tyrosyl-tRNA mimic that blocks translation by labeling and releasing elongating polypeptide chains from translating ribosomes. Puromycin has been used in molecular biology research for decades as a translation inhibitor. The development of puromycin antibodies and derivatized puromycin analogs has enabled the quantification of active translation in bulk and single-cell assays. More recently, in vivo puromycylation assays have become popular tools for localizing translating ribosomes in cells. These assays often use elongation inhibitors to purportedly inhibit the release of puromycin-labeled nascent peptides from ribosomes. Using in vitro and in vivo experiments in various eukaryotic systems, we demonstrate that, even in the presence of elongation inhibitors, puromycylated peptides are released and diffuse away from ribosomes. Puromycylation assays reveal subcellular sites, such as nuclei, where puromycylated peptides accumulate post-release and which do not necessarily coincide with sites of active translation. Our findings urge caution when interpreting puromycylation assays in vivo.